Pegcetacoplan-Empaveli price changes and trends in 2025

Pegcetacoplan (Pegcetacoplan), a complement C3 inhibitor, has entered the market in many countries, but has not yet been approved in mainland China. Therefore, price information still mainly comes from overseas drug distribution systems. According to overseas public drug prices in 2025, the market price of Empaveli in 1080mg/20ml is approximately US$4,700, which is a high-cost complement-targeted therapy drug. As its application expands into complement diseases beyond PNH, price trends and market structure have attracted much attention.

From the perspective of international drug pricing rules, innovative biopharmaceuticals usually maintain relatively high prices in the early stages of their launch, and will subsequently undergo adjustments of varying magnitudes due to competitive pressure, medical insurance negotiations, and changes in the number of patients. The overall price of Pegcetacoplan in 2025 will remain relatively stable and has not declined significantly. The core reasons include high R&D investment, complex production processes, and the market competition for complement system drugs is not yet fully mature. Although there are several C5 inhibitors competing on the market, C3 inhibitors are still in scarcity due to their unique targets, thus maintaining strong price support.

On the other hand,The trend emerging in overseas markets in 2025 is the expansion of the treatment field of complement-related diseases, which makes the potential indications of Empaveli continue to increase. As more clinical studies advance, drug demand is likely to drive supply chain optimization, causing prices to show a slow downward trend in the future, especially in Europe. The medical insurance systems of some countries have begun to discuss including them in the scope of subsidies. This policy change may affect the market price in the medium and long term, gradually reducing the actual cost of medication for patients.

For domestic patients, since the drug has not yet been launched in China and has not been included in medical insurance, they currently mainly rely on overseas channels to obtain it, and the cost will remain at a high level. If it enters the Chinese market in the future, the price trend will depend on multiple factors such as the approval progress, medical insurance negotiations, and the development of domestic alternatives.

Reference materials:https://empaveli.com/